News

May
8
2019

Aristea Therapeutics Appoints Ciara Kennedy, Ph.D. to its Board of Directors

PR Newswire, San Diego – May 8, 2019 – Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced the appointment of Ciara Kennedy, Ph.D. as an independent member of its Board of Directors.

Dec
18
2018

Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S

SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced that it has secured $15M from Novo Holdings A/S (Novo Holdings) in a completed Series A financing. Aristea has also obtained exclusive global rights to its lead program RIST4721, from AstraZeneca. Aristea plans to initiate a Phase 2 clinical study in early 2019. In connection with the financing, Tiba Aynechi, Ph.D and Ken Harrison, Ph.D from Novo Ventures (US), Inc have been appointed to Aristea’s Board of Directors.


Events

Sep
18
2019

Global Genes RARE Patient Advocacy Summit

Aristea is a proud booth exhibitor (booth #24) at Global Genes. Get in touch with us at the event! For more information, click here.

Dates: September 18 – 20

Location: 1380 Harbor Island Drive, San Diego, California, United States of America